TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02311218

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus reuteri DSM 17938 and PTA 5289
Description: Subjects in the test group are given one lozenges with Lactobacillus reuteri DSM 17938 and PTA 5289 in the morning and one in the evening

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo lozenges with no Lactobacillus reuteri DSM 17938 and PTA 5289
Study: NCT02895737

Intervention type: DEVICE
Group type: OTHER
Intervention: TAVI: Edwards SAPIEN 3, Edwards Lifesciences, Edwards Sapien Ultra

Intervention type: DEVICE
Group type: OTHER
Intervention: TAVI: Edwards SAPIEN 3, Edwards Lifesciences, Edwards Sapien Ultra; Sentinel™ Cerebral Protection Systems

Intervention type: DEVICE
Group type: OTHER
Intervention: TAVI: CoreValve® Evolut R™, CoreValve Medtronic
Study: NCT03473457

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART therapy in Acute myeloid leukemia(AML)
Description: one kind of CD38-CART/CD33-CART/CD56-CART/CD123-CART/CD117-CART/CD133-CART/CD34-CART/Mucl-CART therapy in Acute myeloid leukemia(AML)
Study: NCT00534261

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon beta-1a
Description: IM injection
Study: NCT03313908

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: detection of the tumor lesion
Description: non palpable tumor detection with indocyanine green fluorescence and radioactive seed localization
Study: NCT00604214

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drotrecogin alfa (activated)
Description: 24 microgram/kilogram/hour, intravenous, 96 hours (hr)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.9% sodium chloride, intravenous, 96 hours
Study: NCT02895737

Intervention type: DEVICE
Group type: OTHER
Intervention: TAVI: CoreValve® Evolut R™, CoreValve Medtronic; Sentinel™ Cerebral Protection Systems
Study: NCT02063529

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOXIRI + Cetuximab
Description: Cetuximab 500mg/m² + irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FOLFOXIRI
Description: Irinotecan\* 165 mg/m² + oxaliplatin 85 mg/m² + leucovorin 200 mg/m² + 5-FU 2800 mg/m² cont. inf. 46h all on day 1 of each 2 weeks cycle until PD or resectability or to max. 12 cycles
Study: NCT01015001

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active rTMS x sham (placebo) rTMS
Description: Seventeen right-handed patients with DSM-IV TR diagnosis of schizophrenia were randomized in two groups. One arm received 20 sessions of 20 minutes each of low-frequency (1Hz) rTMS applied over the left temporoparietal cortex (LTPC).~The other arm received sham (placebo) stimulation over the LTPC for the same period of time. All patients were considered as having refractory schizophrenia and in use of at least 400mg/day of clozapine and referred auditory hallucinations.
Study: NCT02341079

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine Liposome Injection
Description: Intraoperative intracapsular injection of 266mg of bupivacaine liposome injection diluted to 60mL with 0.9% normal saline.
Study: NCT01015001

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Active rTMS x sham (placebo) rTMS
Description: Seventeen right-handed patients with DSM-IV TR diagnosis of schizophrenia were randomized in two groups. One arm received 20 sessions of 20 minutes each of low-frequency (1Hz) rTMS applied over the left temporoparietal cortex (LTPC).~The other arm received sham (placebo) stimulation over the LTPC for the same period of time. All patients were considered as having refractory schizophrenia and in use of at least 400mg/day of clozapine and referred auditory hallucinations.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: sham rTMS
Description: same coil, same number of pulses but using an angled coil(90degres) over the frontotemporal region

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: (1Hz) rTMS applied over the left temporoparietal cortex
Description: 20 sessions lasting 20 minutes each of low-frequency (1Hz) rTMS applied over the left temporoparietal cortex (LTPC).
Study: NCT00817479

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: 20 MG OF DEXAMETHASONE OR PLACEBO

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo saline
Study: NCT02095496

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intellivent-ASV
Description: 12 hours of mechanical ventilation with intellivent-ASV

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional ventilation
Description: 12 hours of mechanical ventilation with pressure support ventilation
Study: NCT02600754

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IT-PST
Description: 5 sessions of problem-solving therapy by licensed mental health clinicians co-located in an aging-service agency (Meals on Wheels and More)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: IT-SCM
Description: 5 sessions of self-care management support by trained lay advisers co-located in an aging-service agency (Meals on Wheels and More)
Study: NCT02341079

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indwelling femoral nerve block
Description: Femoral nerve block delivered via indwelling femoral nerve catheter with 0.125% bupivacaine.
Study: NCT02814019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idebenone 150 mg film-coated tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study: NCT02597114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AGT-181
Description: intravenous infusion over 3-4 hours
Study: NCT01809652

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Remote Implant Support Capability
Description: Use of audio and video telepresence and remote control of device programmer to allow implant to be supported from a remote location
Study: NCT03697746

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paracetamol
Description: paracetamol 1000 mg vial
Study: NCT03478241

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group 1: single file rotary motion
Description: after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using OneShape Ni-Ti system. the obturation process was completed prior to coronal restoration either with direct or indirect methods

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group 2: multiple file rotary motion
Description: after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using Revo S Ni-Ti system. the obturation process was completed prior to coronal restoration either with direct or indirect methods

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Group 3: single file reciprocal motion
Description: after the previous root canal filling was removed, the shaping procedure of the root canal system was carried out using WaveOne Ni-Ti system. the obturation process was completed prior to coronal restoration either with direct or indirect methods
Study: NCT03697746

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexketoprofen Trometamol
Description: dexketoprofen trometamol 50 mg bulb

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: ıbuprofen 400 mg vial
Study: NCT01379612

Intervention type: OTHER
Intervention: Ultrasonic Elastography
Description: Non-invasive
Study: NCT04350502

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: chest tube drainage
Description: Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g\*3 by day) and clavulanic acid (200mg\*3 by day).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: antibiotic concentration in pleural fluid
Description: Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g\*3 by day) and clavulanic acid (200mg\*3 by day). Repeated samples of pleural fluid and serum will be taken to evaluate antibiotics' concentrations at H0; H½; H1; H2; H3; H4; H8 and H24
Study: NCT00249379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate
Description: Subjects randomized to receive acamprosate 333 mg tablets to be taken 3 times daily to prevent relapse to alcohol dependence
Study: NCT02443402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Subjects will take one pill daily until the day prior to them being discharged from the hospital. Sitagliptin will be dispensed orally at 100 mg/day and at a lower dose 50 mg for patients with glomerular filtration rate (GFR) \< 30-50. If the calculated GFR drops to 30 mL/min/1.73m2 or below, patients will receive study medication 25mg daily
Study: NCT04350502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin + clavulanic acid
Description: Patients with a complicated pleural infection will be managed according to the French guideline with a chest tube drainage associated to a treatment with amoxicillin (2g\*3 by day) and clavulanic acid (200mg\*3 by day). Repeated samples of pleural fluid and serum will be taken to evaluate antibiotics' concentrations at H0; H½; H1; H2; H3; H4; H8 and H24
Study: NCT00891397

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin
Description: Dose of 150mg/day divided in two doses. Increased to 300mg/day then to 600mg/day, always divided in two doses for the day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sugar pill
Study: NCT02443402

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One pill daily until discharge
Study: NCT02178956

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BBI608
Description: BBI608 480 mg orally two times daily (960 mg total daily dose)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 I.V. infusion on Days 1, 8, and 15 of every 4-week cycle

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel 80 mg/m2 I.V. infusion on Days 1, 8, and 15 of every 4-week cycle

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Orally two times daily
Study: NCT02443402

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Regular Human Insulin
Description: Continuous intravenous insulin given to ICU patients with a BG \> 180 mg/DL for two consecutive readings and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Intravenous insulin infusion will be continued until the patient is able to eat and/or transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regular Human Insulin
Description: Continuous intravenous insulin given to ICU patients with a BG \> 180 mg/DL for two consecutive readings and will be started on Regular Human Insulin adjusted to achieve and maintain a BG target between 110 - 180 mg/dL following standard hospital protocol. Intravenous insulin infusion will be continued until the patient is able to eat and/or transferred to non-ICU service. In previous studies, average length of insulin infusion in patients with stress hyperglycemia was 16.9±19 hours and the amount of IV insulin requirement was 18.6±24.3 U/day.
Study: NCT02820350

Intervention type: DEVICE
Group type: OTHER
Intervention: SCD-F40
Description: CRRT with SCD
Study: NCT03569059

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Early Robotic/VR Therapy (EVR)
Description: Subjects will perform state-of-art inpatient usual care therapy. In addition, they will perform an extra 1-hour/day of intensive therapy focusing on the hand in the form of interactive virtual reality games while assisted by robots. This additional treatment will be initiated 5-30 days post stroke.
Study: NCT01407120

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New Beginnings Program
Description: A preventive intervention for divorced families.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: New Beginnings Program
Description: A preventive intervention for divorced families.
Study: NCT04396977

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Histamine 10 mg/ml skin prick
Description: Skin prick through 5 µL histamine diHCl (10 mg/ml)

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Placebo (saline) skin prick
Description: Skin prick through 5 µL saline (0.9% NaCl)
Study: NCT00321516

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aripiprazole
Description: Tablets, Oral, 10, 20, or 30 mg (titrated), once daily, 14 days.
Study: NCT01017497

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: PTV Diameter \< 2.0 cm receives 24 Gy; PTV Diameter 2.0-3.0 cm receives 18 Gy; PTV Diameter 3.1-4.0 cm receives 15 Gy;

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: PTV Diameter \< 2.0 cm receives 24 Gy; PTV Diameter 2.0-3.0 cm receives 18 Gy; PTV Diameter 3.1-4.0 cm receives 15 Gy;
Study: NCT03651076

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Traxi panniculus retraction (Clinical Innovations, LLC)
Description: class I, FDA-exempt, commercially available for use in panniculus retraction during cesarean delivery or other laparotomy
Study: NCT01986335

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTP/HB/Hib Vaccine
Description: DPT/HB/Hib vaccine (Bio Farma)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTP/HB/Hib Vaccine
Description: DPT/HB/Hib vaccine (Bio Farma)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTP/HB/Hib Vaccine
Description: DPT/HB/Hib vaccine (Bio Farma)
Study: NCT05855720

Intervention type: OTHER
Intervention: FIT model project
Description: Several statutory health insurance (SHI) funds have established contracts with hospitals for an alternative remuneration / financing of patients treated in the hospital (FIT hospital). Some of those contracts already started in 2013 and were prolonged. Some FIT contracts will start freshly (until June 2026). These contracts encourage FIT hospitals to test alternative treatment options for their patients (insured with the involved SHI funds), for example fewer inpatient and more outpatient treatment.
Study: NCT03198221

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Golytely
Description: bowel preparation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Golytely
Description: bowel preparation
Study: NCT01986998

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone 1250 mg/24h x3 days
Description: Oral Methylprednisolone 1.250 mg daily, over 1 hour and during 3 consecutive days. 13 capsules will be administered (12 capsules of 100 mg and 1 capsule of 50 mg)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Methylprednisolone 625 mg/24h x3 days
Description: Oral Methylprednisolone 625 mg daily, over 1 hour and during 3 consecutive days. 13 capsules will be administered (6 capsules of 100 mg, 1 capsule of 25 mg and 6 capsules of placebo with the same appearance of capsules of 100 mg)
Study: NCT02993809

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BM-ECs and PRPE

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BM-ECs
Study: NCT03569059

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Dose-Matched Usual Physical Therapy Care
Description: Subjects will perform state-of-art usual physical/occupational care and 10 days of one additional hour of state-of-art usual inpatient and/or outpatient physical therapy/occupational therapy.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Delayed Robotic/VR Therapy (DVR)
Description: Subjects will perform state-of-art inpatient usual care therapy. In addition, they will perform an extra 1-hour/day of intensive therapy focusing on the hand in the form of interactive virtual reality games while assisted by robots. This additional treatment will be initiated 31-60 days post stroke.
Study: NCT03759184

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIL-15
Description: Continuous intravenous (civ) Interleukin-15 (IL-15) at dose levels of 0.5,1 or 2 mcg/kg/day on days 1-5 of cycles 1-6

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rhIL-15
Description: Continuous intravenous (civ) Interleukin-15 (IL-15) at the maximum tolerated dose or the maximum administered dose of 2 mcg/kg/day on days 1-5 of cycles 1-6
Study: NCT03667183

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates
Description: Specific postures in movement according to Pilates guidelines.
Study: NCT03467399

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nucleus 7 Cochlear Implant System
Description: A new cochlear implant sound processor system.
Study: NCT02544386

Intervention type: PROCEDURE
Intervention: MRI and 3D CT scan
Description: Measurement of bone microarchitecture at the legs and wrists by 3D CT Scan and measuring the proportion of fat in the imaging leg bone (MRI)
Study: NCT03863002

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cell
Description: Mesenchymal stem cell transplantation via peripheral vein: 1.0-10x10\^5 MSCs/kg body weight administered via peripheral vein at week 0, 1, 2, 3 weeks
Study: NCT01736878

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sorafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Study: NCT01037114

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Blood sampling
Description: Blood sampling at Year 16, 17, 18, 19 and 20 and at the time of challenge dose administration and 14 days and one month after challenge dose administration (if challenge dose needed).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Engerix-B
Description: Engerix-B will be administered to subjects who are not seroprotected against hepatitis B.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Havrix
Description: Havrix will be administered to subjects who are seronegative for anti-HAV antibodies.
Study: NCT03625856

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Chlorella Vulgaris
Description: Chlorella capsules 1500 mg/day

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Starch 1500 mg
Study: NCT00962611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Copanlisib (Aliqopa, BAY80-6946)
Description: BAY80-6946 given IV over 1 hour every week for three weeks with a one week break until progression or unacceptable toxicities develop.
Study: NCT02514122

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Patients will receive a subcutaneous injection of ketamine (at a dose of 1mg/kg) immediately following surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Patients will receive a subcutaneous injection of saline (at a dose of 0.02cc/kg) immediately following surgery, the evening after surgery, and every 12 hours thereafter for a total of 5 injections.
Study: NCT01699191

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Probiotic

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03377894

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: blunt uterine incision expansion
Description: blunt uterine incision expansion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sharp uterine incision expansion
Description: sharp uterine incision expansion
Study: NCT01082926

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic allogeneic lymphocytes
Description: Given intratumorally

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given intratumorally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Optional correlative studies
Study: NCT02355886

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Given PO

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT02714062

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: po once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521 Mid Dose
Description: po once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: VI-0521 Top Dose
Description: po once daily
Study: NCT04106193

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blended Facilitation
Description: Blended facilitation consists of an External Facilitator and Internal Facilitator to support adoption of intimate partner violence screening practices for WVs treated in primary care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Implementation as usual
Description: Implementation as usual refers to traditional, site-initiated support for screening practices to detect intimate partner violence among WVs treated in primary care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toolkit
Description: All study arms will feature a toolkit meant to guide sites' adoption of intimate partner violence screening among WVs treated in primary care.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Toolkit
Description: All study arms will feature a toolkit meant to guide sites' adoption of intimate partner violence screening among WVs treated in primary care.
Study: NCT03759184

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Intravenous (IV) Obinutuzumab will be administered at a dose of 100 mg on day 4, 900 mg on day 5, 1,000 mg on day 11, and 1,000 mg on day 18 of cycle 1: then 1,000 mg on day 4 of each subsequent cycle
Study: NCT05463822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Transvaginal botulinum toxin A (BTA) injection
Description: Botulinum toxin A (Botox® 100 units) will be injected into the detrusor muscle of the bladder by inserting a needle through the anterior vaginal wall.
Study: NCT02485977

Intervention type: DEVICE
Intervention: Magnetic resonance Imaging
Description: MRI study will be performed on 1.5 Tesla magnet, during the administration of Gadolinium